This is a contrast between Karuna Therapeutics Inc. (NASDAQ:KRTX) and Immune Design Corp. (NASDAQ:IMDZ) based on their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings and valuation. The two companies are Biotechnology and they also compete with each other.
Valuation and Earnings
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Karuna Therapeutics Inc.||20||0.00||N/A||-1.27||0.00|
|Immune Design Corp.||N/A||0.00||N/A||-1.14||0.00|
Table 1 shows the gross revenue, earnings per share (EPS) and valuation for Karuna Therapeutics Inc. and Immune Design Corp.
Table 2 shows us the return on equity, net margins and return on assets of both companies.
|Net Margins||Return on Equity||Return on Assets|
|Karuna Therapeutics Inc.||0.00%||0%||0%|
|Immune Design Corp.||0.00%||0%||0%|
The table given features the ratings and recommendations for Karuna Therapeutics Inc. and Immune Design Corp.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|Karuna Therapeutics Inc.||0||0||0||0.00|
|Immune Design Corp.||0||2||0||2.00|
Competitively the consensus price target of Immune Design Corp. is $5.93, which is potential 1.37% upside.
Insider & Institutional Ownership
Roughly 0.3% of Karuna Therapeutics Inc. shares are owned by institutional investors while 59.09% of Immune Design Corp. are owned by institutional investors. Insiders owned 33.1% of Karuna Therapeutics Inc. shares. On the other hand, insiders owned about 1.35% of Immune Design Corp.’s shares.
In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Karuna Therapeutics Inc.||-9.21%||-12.71%||0%||0%||0%||-8.44%|
|Immune Design Corp.||0%||0%||0%||0%||0%||0%|
Immune Design Corp. beats on 3 of the 5 factors Karuna Therapeutics Inc.
Immune Design Corp., a clinical-stage immunotherapy company, engages in the research and development of in vivo treatments for cancer. It primarily develops oncology product candidates based on its ZVex and GLAAS product discovery platforms. The company's products include CMB305, which is in Phase 2 trial for the treatment of NY-ESO-1 tumor antigen; LV305 that is in Phase 1 trial for the treatment of patients with relapsed or metastatic melanoma, sarcoma, ovarian cancer, or non-small cell lung cancer that express NY-ESO-1; and G100, an intratumoral immune activation product candidate for the treatment of patients with Merkel cell carcinoma and non-Hodgkin Lymphoma. In addition, its technologies are also used in the fields of infectious diseases and allergies. The company has license agreements with California Institute of Technology, University of North Carolina at Chapel Hill, TheraVectys SA, Infectious Disease Research Institute, MedImmune LLC, and Sanofi; and a collaboration agreement with Sanofi Pasteur. Immune Design Corp. was founded in 2008 and is headquartered in Seattle, Washington.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.